Psoriatic arthritis: a review
Article first published online: 14 DEC 2009
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Volume 8, Issue 5, pages 332–339, May 2010
How to Cite
Amherd-Hoekstra, A., Näher, H., Lorenz, H.-M. and Enk, A. H. (2010), Psoriatic arthritis: a review. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 8: 332–339. doi: 10.1111/j.1610-0387.2009.07334.x
- Issue published online: 22 APR 2010
- Article first published online: 14 DEC 2009
- Submitted: 18.9.2009 | Accepted: 4.11.2009
- psoriatic arthritis;
- tumor necrosis factor;
- TNF-alpha antagonist
Psoriatic arthritis (PsA) is an immunologically triggered, chronic inflammatory arthropathy, which can have a lasting influence on the quality of life of affected individuals. An early diagnosis is essential in order to institute adequate therapy. Both dermatologists and rheumatologists should be involved in the diagnosis and management of the disorder.
Mild forms can be managed with NSAID and systemic corticosteroids. In acute forms with a confirmed diagnosis and oligo- to polyarticular involvement, disease-modifying therapy with DMARD (Disease-Modifying Antirheumatic Drugs) is indicated. New studies of PsA show that tumor necrosis factor (TNF) plays a central role in mediating inflammation. For this reason, TNF-α antagonists have become more and more important as a second-line therapy for PsA.